Physician profile
Heidi M Daugherty
NPI 1346497906
$2,938.29
in general payments reported to CMS, 2019-2025
42 companies · $738 in 2025
The $738 reported for 2025 was more than what 80% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $389 · 2022: $523 · 2023: $629 · 2024: $659 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $331.47 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $218.89 | 2021-2025 | Mounjaro, Jardiance, Baqsimi |
| Corcept Therapeutics | $182.81 | 2023-2025 | Korlym |
| Dexcom, INC. | $158.56 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $141.63 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $138.50 | 2022-2025 | |
| Abbott Laboratories | $136.76 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $136.43 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.97 | 2021-2025 | Jardiance, Tradjenta |
| Amgen INC. | $124.30 | 2021-2025 | Tepezza, Evenity, Prolia |
| Insulet Corporation | $117.90 | 2021-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $78.52 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $70.29 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $62.76 | 2025 | Yorvipath |
| Pfizer INC. | $62.55 | 2022-2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $60.44 | 2023-2024 | Tymlos |
| Medtronic, INC. | $58.11 | 2021-2025 | Minimed 780g |
| Ibsa Pharma INC. | $56.65 | 2021-2022 | |
| Beta Bionics, INC. | $54.71 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amphastar Pharmaceuticals, INC. | $53.00 | 2023-2025 | Baqsimi |
| Nevro Corp. | $42.12 | 2021-2024 | Senza |
| Recordati_rare_diseases_inc. | $37.16 | 2021-2023 | Isturisa, Signifor Lar |
| Abbvie INC. | $34.97 | 2022-2025 | |
| Globus Medical, INC. | $33.16 | 2025 | Senza |
| Amneal Pharmaceuticals LLC | $32.73 | 2022-2025 | Unithroid |
| Esperion Therapeutics, INC. | $32.09 | 2021-2025 | Nexletol |
| Ipsen Biopharmaceuticals, INC | $30.44 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $29.90 | 2023-2024 | Contrave |
| Astrazeneca Pharmaceuticals LP | $29.64 | 2021-2022 | |
| Amarin Pharma, INC. | $26.41 | 2021-2023 | |
| Averitas Pharma INC. | $26.41 | 2024 | Qutenza |
| Alexion Pharmaceuticals, INC. | $24.74 | 2022 | |
| Vivus LLC | $23.20 | 2021 | |
| Neurocrine Biosciences, INC. | $22.65 | 2025 | |
| Grt US Holding, INC. | $22.37 | 2022 | |
| Sequel Med Tech, LLC | $22.37 | 2025 | Twiist |
| Soleno Therapeutics, INC. | $21.19 | 2025 | Vykat Xr |
| Evoke Pharma, INC. | $19.74 | 2025 | |
| Amryt Pharma Holdings LTD | $13.87 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $13.82 | 2021 | |
| Clarus Therapeutics INC. | $13.65 | 2021 | |
| Mannkind Corporation | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.